VIRTUAL DISCUSSION | Access To Innovative Therapies – The Reblozyl Case | 7 October 2021

After receiving numerous questions from patients regarding the innovative treatment for β-thalassaemia Reblozyl (luspatercept), approved for use in the US, Europe, and Canada, TIF proceeds to organise an interactive, online discussion that will allow participants to get reliable information from eminent international haematologists on this prescription medicine and express their queries and concerns directly to the experts!

 Thursday, 7 October 2021
 13:00 -15:00 CEST / 07:00-09:00 EDT

Join us in this highly interesting discussion through a simple registration HERE

View the Agenda

What is Reblozyl?

Reblozyl is a brand-name prescription medication. It’s used to treat anemia (low red blood cell count) in adults with certain blood disorders. Specifically, it’s used:

• In adult patients with β-thalassaemia who require regular red blood cell transfusions,
• In anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

More specifically, Reblozyl is a type of drug called an erythroid maturation agent. It helps raise the number of healthy, mature red blood cells in the blood. Reblozyl is a biologic (a drug made using living cells) that contains the active drug luspatercept-aamt. The drug is administered by subcutaneous injection (an injection under the skin), typically once every 3 weeks.

More Info:

TIF has developed a Patient Information Leaflet especially for Reblozyl than can be accessed HERE

View Reblozyl in Clinical Trials HERE